FDA Grants Priority Review for ZAYNICH NDA Submission by Wockhardt Bio AG
The FDA has granted priority review for the NDA submission of ZAYNICH, containing cefepime hydrochloride and zidebactam.
Asset / Drug
Drug and asset intelligence for ZAYNICH with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.